Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Symbotic Shares Fall After Mixed Q1 Earnings Report

By Erica Kollmann
February 5, 5:55 PM
Symbotic reported quarterly losses of 2 cents per share which beat the analyst consensus estimate of a loss of 6 cents per share by 66.67% and is a 83.33% increase over losses of 12 cents per share from the same period last year. The company reported quarterly sales of $368.45 million, missing the analyst consensus estimate of $368.86 million by 0.11% and representing a 78.59% increase over sales of $206.31 million the same period last year.

SYM

Read More
2 minute read

Simon Property Group Reports Better-Than-Expected Q4 Results, Raises Quarterly Dividend

By Erica Kollmann
February 5, 5:45 PM
Simon Property Group reported quarterly FFO of $3.69 per share which beat the analyst consensus estimate of $3.34 by 10.48%. The company reported quarterly sales of $1.53 billion which beat the analyst consensus estimate of $1.36 billion by 12.38% and represents a 9.07% increase over sales of $1.4 billion from the same period last year.

SPG

Read More
1 minute read

NXP Semiconductors Climbs After Better-Than-Expected Q4 Earnings

By Erica Kollmann
February 5, 5:26 PM
NXP reported quarterly adjusted earnings of $3.71 per share which beat the analyst consensus estimate of $3.63 by 2.2% and represents a 0.54% decrease over earnings of $3.73 per share year-over-year. The company reported quarterly sales of $3.42 billion, beating the analyst consensus estimate of $3.40 billion by 0.65% and representing a 3.32% increase over sales of $3.31 billion from the same period last year.

NXPI

Read More
1 minute read

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer

By Erica Kollmann
February 5, 1:31 PM
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of $92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.

INCY

Read More
2 minute read

Why Adverum Biotechnologies Stock Is Trading Higher

By Erica Kollmann
February 5, 11:50 AM
Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock's 30-day volume-weighted average price, and the financing is expected to close on Feb. 8. Adverum anticipates the gross proceeds from the private placement to be approximately $127.5 million, before deducting any offering related expenses and are expected to be sufficient to fund the current operating plan into late 2025.

ADVM

Read More
1 minute read

Why BioRestorative Therapies Stock Is Up Today

By Erica Kollmann
February 5, 11:42 AM
BioRestorative Therapies presented the data at the Orthopaedic Research Society 2024 Annual Meeting on Sunday and hosted a webcast and slideshow to present the data to stakeholders on Monday morning before the market open. BioRestorative said data that was collected at weeks 26 and 52 post-injection demonstrated a positive trend compared to baseline.

BRTX